Skip to content
lifestyle.wordsjournal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
InnoCare Pharma
InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China
September 8, 2026
InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved
August 24, 2026
InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment-Naive AML in China
August 18, 2026
InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China
August 3, 2026
InnoCare’s TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study
July 27, 2026
InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
May 13, 2026
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren’s Syndrome in China
May 7, 2026
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
May 6, 2026
InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE
April 28, 2026
InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability
April 23, 2026
1
2
Next Page
→